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Abstract 
 
Objective: The objective of this study was to describe the prevalence of sexually transmitted co-
infections and assess factors associated with a single infection and co-infections.  
Methods: A total of 388 women were included in this study. At enrollment of the EVRI trial women 
were tested for five STIs: Human papilloma virus (HPV), Chlamydia trachomatis, Neisseria 
gonorrhoeae, Herpes simplex virus-2 (HSV-2) and Treponema pallidum. Prevalence of STI 
infections and proportion of women with different combinations of co-infections were calculated. 
Factors associated with single infection and STI co-infection were assessed using a polytomous 
logistic regression model and odds ratio (OR) and 95% confidence intervals (95% CI) were 
reported as the measure of association. 
Results: Prevalence of a single STI and concurrent STI co-infections were high. The most 
common STI co-infection pattern was HPV-HSV (32%), followed by HPV-chlamydia (17%). The 
odds of a single STI compared to no STIs were significantly higher (OR 3.02, 95% CI: 1.05-8.64) 
and the odds of concurrent STIs compared to no infection were significantly higher (OR 3.86, 95% 
CI: 1.42-10.48) for women with three or more lifetime partners compared to one life time partner.  
Conclusions: STIs, single and multiple concurrent infections, are common among this cohort of 
South African women. These results strengthen the recommendation that STI screening and 
treatment needs to be a component of multiple intervention strategies among high-risk women 
residing in communities with high STI prevalence. 
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Introduction 
 
Sexually transmitted infections (STIs) are a major public health concern in many developing 
countries. Women are more likely to bear the burden of these infections but less likely to seek 
medical treatment.[1] STIs are responsible for severe adverse reproductive outcomes and 
published reports from the World Health Organization (WHO) suggest that Africa remains the 
continent worst affected.[2] Human-papilloma virus (HPV) causes cervical cancer, and other STIs 
like Chlamydia trachomatis (chlamydia) and Treponema pallidum (syphilis) are major causes of 
both maternal and childhood morbidity during pregnancy.[3] High prevalence of STIs in many 
developing countries has been attributed to a multifactorial etiology where there is a complex 
interplay of demographic, socio-economic, and sexual behavioral factors.[4] 
Current Epidemiology of HPV  
HPV infection, a double stranded DNA virus, is the most common STI and a major public health 
issue globally. Currently more than 100 different HPV genotypes have been identified, and of 
these 13 genotypes (HPV 16,18,31,33,35,39,45,51,52,56,58,59 and 68) have been designated 
high-risk (HR-HPV)  or carcinogenic due their potential to cause high-grade intraepithelial lesions 
(HSIL’s), the precursor to cervical cancer, and cancer. Most women naturally clear HPV infections 
(low-risk HPV 12-month clearance 12.2%, 95% confidence interval (CI): 9.6%-15.4%, but some 
HR-HPV genotypes, especially HPV 16, tend to persist (12-month clearance 9.5%, 95% CI: 7.5%-
11.9% and may lead to neoplasia.[5] Previous studies have shown that co-infections with other 
STIs lead to persistence of HR-HPV infections.[6] A meta-analysis of studies worldwide that 
included nearly 160,000 females with normal cervical cytology had ~10% HPV prevalence and 
the highest regional cervical HPV prevalence was 22% among women in Africa.[7] HPV infection 
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accounts for 100% of invasive cervical cancers, and nearly 70% of these cancers are caused by 
HPV genotypes 16 and 18.[8] Apart from cervical cancer, approximately 90% of anal, 43% of 
vulvar, 70% of vaginal and nearly 50% of penile cancers are attributed to a persistent HPV 
infection.[9] Among women in rural sub Saharan Africa, one study reported a cervical HPV 
prevalence of 40%.[8] 
It has been suggested that there is a rapid cervical HPV and STI co-infection acquisition after 
sexual debut. HPV vaccines are prophylactic and are therefore recommended prior to sexual 
debut, typically ages 9-12.[10] There are currently three HPV vaccines (Gardasil, Gardasil 9, and 
Cervarix) that have shown efficacy in preventing cervical disease. Data from the Centers for 
Disease Control and Prevention (CDC) indicate that there is nearly 56% reduction in HPV 
infections among teenage girls in the United States since the inception and commercial use of 
the HPV vaccines.[11] The 9-valent vaccine is estimated to prevent anogenital warts and 90% of 
cervical disease by providing protection from HPV 6,11,16,18,31,33,45,52 and 58.[9] 
Current Epidemiology of other STIs 
The WHO estimates that globally, there are about 340 million new cases of the four main curable 
STIs (Chlamydia, gonorrhea, syphilis and trichomoniasis) each year.[12] 
Chlamydia trachomatis, an intracellular bacterium, is the most common bacterial STI in the United 
States and globally.[13] It commonly affects the urethra in males and the urethra and the cervix 
in females. Presence of these bacteria in the cervix is an important risk factor for persistent HPV 
infection and ascending chlamydial infections are common in females that can ultimately 
contribute to ectopic pregnancy and infertility.[6] Most cases of genital chlamydia are 
asymptomatic, only identified through screening procedures, providing a constant source of 
efficient disease transmission. In a study carried out by CDC, the prevalence of chlamydia 
infection in persons aged 14-39 years was 1.7% (95% CI 1.4%-2.0%). However, the prevalence 
among sexually active females aged 14-24 years was 4.7% and 13.5% among non-Hispanic black 
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females.[14] The WHO reports that there were nearly 100 million prevalent cases of chlamydia 
and nearly 105 million incident cases worldwide in 2008 which represents a 5% increase from 
2005.[2] Prevalence of chlamydial infection varies from 2.1% (95% CI 1.6-4.1) among women 
aged 20-64 years in China [15] to 8% (95% CI 5%-11%) among women in rural sub-Saharan 
Africa [8], and 19.5% (95% CI 14.9%-24.1%) among women in South Africa.[16] 
Neisseria gonorrhoeae, a gram-negative diplococci, is the second most prevalent bacterial STI 
and is the second most commonly reported infectious disease in the USA.[13] It can cause either 
a localized pelvic infection or a generalized systemic infection called disseminated gonococcal 
infection (DGI). It is commonly found in the urethra in males and the cervix in females. The WHO 
estimated the global incidence of gonorrhea in 2008 to be 106 million cases representing a 21% 
increase from 2005.[2] However, an accurate estimation of gonorrhea incidence is difficult 
because of the lack of diagnostic and reporting capabilities around the world. The highest 
gonorrhea prevalence was seen in Africa, ranging from 1.5% in west and central Africa to 4.9% 
in east and southern Africa. In one study among women in rural sub-Saharan Africa, gonorrhea 
prevalence was 14% (95% CI 10%-19%) [8], and 16.5% (95% CI 12.9%-20.2%) in South 
Africa.[16] A population-based study in China reported 0.08% (95% CI 0.02-0.4) prevalence 
among women aged 20-64 years.[2] The incidence of gonorrhea in the United States was 106 
cases per 100,000 persons in 2013, with the incidence 12 times higher in blacks compared to 
whites (427 vs 35 per 100,000 persons). For women, the incidence was highest for those aged 
20-24 years (542 cases per 100,000 persons).[13] Gonorrhea incidence has been higher in 
males, as the disease in more asymptomatic in females and possibly due to higher incidence of 
gonorrheal infection in men having sex with men. 
Treponema pallidum, a gram-negative spirochete, causes syphilis characterized by a 
symptomatic early stage and an asymptomatic latent stage. Most syphilis research is focused on 
the early stage, since transmission is unlikely in the latent stages. The estimated syphilis 
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incidence in the United States was 5.3 cases per 100,000 persons in 2013 representing an 
increase from 2.9 cases per 100,000 in 2005.[13] There is a major racial difference in syphilis 
incidence in the US, with the incidence being 5.2 times higher in blacks compared to whites (27.9 
vs 5.4 per 100,000 persons). The incidence among women was 0.9 per 100,000 and black women 
were 13.3 times more likely to have incident syphilis infection compared to white women (4.0 vs 
0.3 per 100,000 person).[13] The WHO reports that there were nearly 12 million incident cases of 
syphilis worldwide in 2008, with highest incidence seen in South East Asia and Africa.[2]  
Prevalence of syphilis varies from 12% (95% CI 8%-17%) [8] among women in rural sub-Saharan 
Africa to 7.5% (95% CI 5.2%-9.8%) [16] in South Africa. There is a high rate of HIV co-infection 
in people who are infected with syphilis and most cases of primary and secondary syphilis occur 
among MSM.[13] 
Herpes Simplex Virus-2 (HSV-2), a double strand DNA virus, is ubiquitous and a highly 
contagious virus that is transmitted by contact with an infected area. HSV-2 seropositivity has 
emerged as a major public health issue in sub-Saharan Africa as HSV-2 infection increases the 
risk of HIV transmission and acquisition.[17, 18] Similarly, HSV-2 seropositivity has been 
proposed to be a marker of sexual risk behaviors in young adults.[17] There are around 50 million 
people who are seropositive for HSV-2 in the US.[13] The age-adjusted prevalence of HSV-2 in 
the US is 17% (95% CI 15.8%-18.3%), however genital HSV is often undiagnosed as it is mostly 
asymptomatic.[19] The seroprevalence of HSV-2 increases with age, number of sexual partners, 
and is higher in women compared to men.[19] As with other STIs there is a racial difference in 
the prevalence of HSV-2 with it being three times higher in blacks compared to whites (39% vs 
12%).[13] The WHO reports that a higher prevalence of HSV-2 is seen in Africa and South East 
Asia and the lowest prevalence is seen in Europe (18% of women and 13% of men).[2] A study 
performed among women in rural sub- Saharan Africa showed an extremely high HSV-2 
prevalence of 83% (95% CI 78%-87%) [8], with the seroprevalence increasing with age.  
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Factors associated with STIs 
Age: Age has been associated with the risk of STI, however there are study specific variations on 
STIs influenced by age. A study among women in rural sub Saharan Africa reported gonorrhea 
infection being more prevalent in the younger age group, 14-20 years (P<0.01),[16] whereas there 
was no age-related association with chlamydia. Syphilis showed increased prevalence with age 
but the association was not statistically significant (P=0.67). The frequency of HSV-2 antibodies 
increased significantly with age (P<0.01) and the lowest prevalence was seen in the youngest 
age group. Prevalence of LR-HPV and HR- HPV decreases with age in women, with the 
prevalence being highest in the youngest age group, 14-20 years (P<0.001).[8] Among migrant 
workers in South Africa age was associated with the risk of STI, but the effect of age diminished 
when migration status was considered [4].Initial analysis of the current EVRI trial showed that 
prevalence of HPV was highest among youngest women, aged 16-17 and decreased with age. 
Prevalence of gonorrhea and chlamydia were highest in younger women and significantly 
decreased with age. The prevalence of syphilis was highest at age 16 (20%) and was significantly 
lower among women aged 17-24 (3-10%).[10] 
Sociodemographic and Behavioral Risk Factors: Education, marital status, age at first sexual 
intercourse, life-time number of male sexual partners, and number of new sexual partners have 
all been established as important risk factors that determine the prevalence of STIs. Women who 
reported more than one lifetime partner had higher risk of cervical gonorrhea infection (odds ratio 
(OR) 2.8, 95%CI: 1.2-6.2). Women who were divorced or widowed had higher risk of syphilis (OR 
3.6, 95% CI: 0.6-21.9) and South African women who were single (OR 5.6, 95% CI: 1.8-17.3) and 
who were living with a partner (OR 2.3, 95% CI: 1.3-4.1) had significant higher risk of chlamydia 
infection.[8] One prospective study showed that having more than two sexual partners in the past 
increased the risk of acquiring chlamydia (OR 19.2, 95%CI: 1.2-296.7) and gonorrhea (OR 3.4 
95%CI: 0.3-33.2) infection.[16] In South Africa, the risk of acquiring chlamydia (OR 1.7, 95% CI: 
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1.3-4.1) and gonorrhea (OR 2.0, 95% CI: 1.2-3.4) was higher for women who had completed 
secondary or higher level of school education [16] and for women who had received money or 
some form of compensation for the sexual activity. Migrant men (OR 1.54, 95% CI: 1.0-2.3), who 
leave their home primarily for better paying jobs, and their partners (OR 1.2, 95% CI: 0.7-1.88) 
also reported a higher risk of contracting a STI.[4] 
Co-infection Status:  Co-infection is believed to act bi-directionally whereby being infected with 
one STI increases the risk of acquiring another STI. Women who were HIV-positive were more 
likely to have HPV DNA detected at the cervix (47% vs 37%, OR 1.6, 95% CI: 0.5-3.5). It was 
also shown that women who tested positive for syphilis were more likely to test positive for HPV 
DNA (OR 4.1, 95% CI: 1.9-9.1).[8] Presence of chlamydia or gonorrhea infection was also 
associated with higher likelihood of HSV-2 antibody positivity (OR 2.4, 95% CI: 1.1-5.4) and the 
presence of either of gonorrhea or syphilis increased the likelihood of being infected with 
chlamydia infection (OR 2.3, 95% CI: 1.0-5.1).[8] A study in South Africa reported that being 
positive for active syphilis increased the likelihood of acquiring gonorrhea (OR 4.0, 95%CI: 1.2-
13.3), being positive for gonorrhea increased the likelihood of acquiring chlamydia (OR 4.7, 
95%CI: 2.4-9.5) and being positive for chlamydia increased the likelihood of acquiring gonorrhea 
(OR 5.0, 95%CI: 2.5-9.9). Having an incident HIV infection significantly increased the likelihood 
of getting a chlamydia (OR 7.3, 95%CI: 2.9-18.6) and a gonorrhea infection (OR 5.5, 95%CI: 1.9-
16.3).[16] Synergy between STI risk factors, particularly sexual behavior and biological 
mechanisms like mucosal disruption, alteration of organism’s natural history could provide 
explanation as to why women with one STI are more likely to have infection with another STI.[20] 
Although most of the studies suggest HIV infection increases risk of acquiring other STIs, recent 
studies among men and women have found an increased risk of HIV among HPV-positive 
individuals [15] and it is possible that a portion of HIV infections could be prevented through HPV 
vaccination. The Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) is a placebo controlled 
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Phase II Trial that was carried out to assess the feasibility of a HPV vaccine trial in a female 
population aged (16-24) living in the Western Cape, South Africa who are at high risk for HPV 
and HIV infections. The secondary aim of this trial was to estimate the prevalence of HIV, HPV 
and other sexually transmitted infections (STI) by age. The EVRI trial showed high rates of accrual 
of eligible females (93%) and high completion rates of the three-dose HPV vaccine series (91%) 
among 402 sexually active HIV-negative females.  
Thesis Specific Aims 
Given that women in South Africa share a high burden of HIV and sexually transmitted infections, 
the first objective was to describe the prevalence of STI co-infections (HPV, chlamydia, 
gonorrhea, syphilis and HSV-2) among young women from the Western Cape at enrollment in 
the EVRI trial as well as the proportion of women with the different combinations of co-infections. 
The second objective was to assess factors associated with a single infection and multiple 
sexually transmitted co-infections. 
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Methods 
 
Population 
The EVRI trial was conducted in the Western Cape, South Africa among women ages 16-24 who 
were enrolled in the study from November 2012 to July 2013.[10] Participants were recruited using 
brochures, flyers and word of mouth, inviting them to participate in a vaccine research study 
against cervical cancer. Two clinic sites, Kraaifontein day hospital and Bloekombos primary health 
care clinic, were used as the recruitment centers. These study sites were chosen because of 
previous clinical data that indicated high HIV prevalence as well as the availability of infrastructure 
to carry out this trial. Participants were informed about the link between HIV and HPV. They were 
also informed that the study results would be used to determine the necessity of a larger future 
trial to evaluate the potential role of HPV vaccine in preventing HIV infection. Women who 
participated in the study were compensated for their time and transportation with an aim of 
improving compliance in the study. 
Participants who showed interest in the study were screened based on the eligibility criteria 
(Appendix A). Those who did not meet eligibility requirements or those who were unwilling and 
later dropped out were excluded from the study. Briefly, HIV-negative women aged 16-24 years, 
not pregnant, without a history of abnormal cervical Pap smear, and not enrolled in any other HIV 
trial were eligible for enrollment into this study. A total of 924 women were approached to 
participate in this trial. 404 of these women were not enrolled in the study due to ineligibility and 
an additional 41 either became unwilling to participate or dropped out of the study (Figure 1). 479 
women were enrolled into the study who met eligibility after administration of the questionnaire 
(Appendix A). HIV and pregnancy testing at enrollment was conducted. Twelve women were 
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pregnant, 57 tested positive for HIV, 1 was both pregnant and HIV positive. These 70 women 
were not randomized due to trial ineligibility. Seven women dropped out of the trial, which left 402 
women who were randomized to receive the vaccine or placebo. Women who were pregnant 
were referred for related medical care and were excluded from the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The EVRI Study: Study Protocol Flowchart 
Approached (n=924)  
Not Enrolled (n=445) 
 Ineligible (n=404) 
 Unwilling (n=35) 
 Dropped (n=6) 
Enrolled (n=479)  
Initial Non-randomized Cohort (n=77) 
 HIV-Positive (n=57) 
 Pregnant (n=12) 
 HIV-Positive and Pregnant 
(n=1) 
 Dropped out (n=7) 
 
Final Randomized 
Cohort 
 (n=402)  
Incomplete Surveys 
(n=12)  
Final Non-randomized Cohort 
 (n=65)  
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This trial was performed in accordance with the ethics committee review and was approved by 
the Institutional review boards of USF (University of South Florida) and Stellenbosch University, 
South Africa. Parental consent was obtained for children (aged 16-17 years) participating in this 
trial and getting tested for HIV. Parents were informed about their child’s HIV test results. 
Study Protocol 
During the enrollment phase of the EVRI trial, participants were asked about their health, socio-
demographic and sexual history using a tablet-based questionnaire that was available in three 
regional languages (English, Xhosa & Afrikaans). The tablet-based questionnaire was a source 
of initial confusion in the trial as 116 participants reported not having had vaginal intercourse 
during the eligibility screening. Later, in-depth qualitative interviews with the participants revealed 
the confusion was with the term “vaginal”. Different types of intercourse was explained to the 
participants to prevent misinterpretation in reported sexual history. A similar tablet-based 
questionnaire was used during the month 7 visit to record health, socio-demographic and sexual 
history. 
As described, the EVRI trial was a Phase II randomized controlled trial involving the 4-valent HPV 
vaccine (Gardasil). Women were randomized 1:1 to receive either the Gardasil vaccine or placebo 
(saline). The EVRI trial was double blinded study where the participant’s vaccination status was 
unknown to the staff and study investigators with the exception of the pharmacist who allocated 
the vaccines. The vaccine and placebo were administered at enrollment (baseline), month 2 and 
month 6. Participants were followed for 1 month (Month 7) after the third vaccine dose, when 
unblinding of the vaccination status occurred and the study participants who were in the placebo 
arm of the trial were offered the chance of receiving Gardasil at no charge. 
Gonorrhea and chlamydia were tested using urine samples at enrollment and Month 7. Herpes 
Simplex Virus (HSV)-2 antibodies and syphilis testing was measured in the participant’s serum 
sample at baseline (enrollment).  Participants who tested positive for chlamydia, gonorrhea, or 
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syphilis were made aware of their STI results and were provided treatment. Counselling regarding 
safe sexual practice was provided to all the study participants at each clinical visit, regardless of 
age, as mandated by South African guidelines, including providing condoms free of charge. 
During each of the three follow up visits, a pregnancy test using a urine sample and a rapid HIV 
test were performed. As stated, any participant with a positive pregnancy test was referred to care 
and was removed from the EVRI trial. Participants with a positive rapid HIV test were retested 
with two different confirmatory tests and those that were confirmed positive (n=3) were referred 
to care but remained on the trial, but were removed from HPV related analysis as HIV is known 
to influence HPV natural history.[21]  
External genitalia were examined at enrollment and Month 7 for any signs of skin pigmentation, 
lesions, discharge and nodules. This was followed by a speculum examination of the vagina and 
a digital vaginal examination. Samples obtained from the vulva/labia and endo/ectocervical 
specimens were collected for HPV detection at enrollment and Month 7. Specimens for HPV 
analysis were obtained using a prewetted Dacron Cotton Swab placed in an STM collection vial 
(manufactured by Digene Corporation, Maryland) and were stored at 40C before testing. If the 
Pap smear cytology (collected using SurePath method) results were greater than atypical 
squamous cells of undetermined significance (ASCUS)/low-grade squamous intraepithelial 
lesions (LSIL), the participant was referred to a local clinic to perform a repeat Pap smear test 
and clinical management was indicated. Participants with Pap cytology results that showed high-
grade squamous intraepithelial lesions (HSIL) were referred to the study gynecologist for 
colposcopy and clinical management.  
Laboratory Analyses 
Gonorrhea and chlamydia were detected using the Amplex CT/NG real- time detection method 
(Seegene, South Korea).[10] Syphilis was detected using Captia Syphilis (Treponema pallidum)-
G assay (Trinity Biotech, Jamestown, NY). Specimens were reported positive only if reconfirmed 
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positive by a repeat test using the same assay.[22] HSV-2 antibody status was assessed using 
the Captia HSV-2 type specific IgG enzyme-linked immunoassay (EIA, Trinity Biotech). HIV status 
was assessed using the rapid testing method, Determine HIV-1/2 Ag/Ab combo immunoassay 
(Alere Healthcare, Waltham, MA). Specimens that were HIV-positive in the rapid test underwent 
two confirmatory tests with the Abbott HIV Ag/Ab combo (Abbott, Wiesbaden, Germany) and the 
BioMerieux VIDAS HIV DUO assay (BioMerieux Inc., Durham, NC). 
HPV analysis was performed on the DNA that was extracted from the cervical cell specimens 
using the Qiagen Media Kit and amplified by polymerase chain reaction (PCR) with the 
PGMY09/11 L1 consensus primer system and AmpliTaq Gold polymerase (Perkin-Elmer, 
Norwalk, CT). HPV genotyping was performed on all specimens, regardless of PCR results, using 
the Linear Array HPV Genotyping Test (Roche Diagnostics, Indianapolis, IN). This test detects 37 
HPV genotypes including 13 high-risk HPV genotypes (HR-HPV): 
16,18,31,33,35,39,45,51,52,56,58,59,68 and 24 low-risk HPV genotypes (LR-HPV): 
6,11,26,40,42,53-55,61,62,64,66,67,69-73,81-84,89,IS39.[23] The Linear array method, 
however, cannot detect HPV 52 co-infection in the presence of HPV genotypes 33, 35 or 58, so 
some of the HPV 52 co-infections may have gone undetected in this trial.  
Statistical Analysis 
Among the 402 women enrolled, three participants with false negative results for HIV, five 
participants with inadequate samples for HPV detection, and six participants who were β-globin 
and HPV DNA negative at enrollment were removed from the analysis. Specimens from the 
remaining 388 participants at enrollment were used in the analysis, as described in Figure 2. 
Statistical analyses was performed using SAS ® 9.4 software (SAS Institute Inc., Cary, NC, USA). 
A probability of less than 0.05 was considered statistically significant. 
  
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  The EVRI Study: Final Sample Size Flowchart for Analysis 
 
At enrollment women were tested for five STIs: HPV, chlamydia, gonorrhea, HSV-2 and syphilis 
and were categorized into three categories: single infection, STI co-infection, and no infection. 
Single infection was defined as having any one of the five STIs, co-infection was defined as having 
a combination of two or more of these STIs, and no infection was defined as being negative for 
all STIs.  
Enrollment demographic and sexual health characteristics were compared between the three 
groups using Wilcoxon rank-sum test for continuous variables, and Fisher’s exact test or chi-
squared test for categorical variables. HPV infection was further classified as having any HPV 
genotype or HR-HPV genotype. Demographic variables were chosen based on associations with 
Final Randomized Cohort  
(n=402) 
Excluded from Analysis: 
 HIV Positive ( n=3) 
 Inadequate sample for HPV detection (n=5) 
 β-globin and HPV DNA negative (n=6)  
Final Sample size for Analysis 
(n= 388) 
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STIs shown in previous studies. [9, 10].  Unadjusted and adjusted odds ratios assessing factors 
associated with STI co-infection were calculated using a polytomous logistic regression model 
comparing the three groups of women: STI negative, single STI infection and STI co-infections. 
Odds ratio (OR) and 95% confidence intervals (95% CI) were reported as the measure of 
association. A multivariate model was created using a backward selection procedure with a p-
value of 0.20 to obtain the most parsimonious model. To determine the presence of effect 
modification, interactions were tested between the main effect variable and the covariates 
included in the model. Finally, to test whether our final model provided a good fit to the data, a 
Goodness-of-Fit test was performed. 
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Results 
 
Demographic Characteristics (Any HPV) 
When HPV was categorized as “any HPV” infection, 12% (n=48) women had no STIs, 34% 
(n=131) were infected with at least one and 54% (n=209) women had two or more STI co-
infections (Table 1a). The median age of participants with “no infection” and participants with co-
infections was 20 years (range, 16-24) whereas it was 21 years for the single infection group 
(range, 16-24). Education level was significantly different (p=0.02) between the three groups; 
women with STI co-infections had a larger proportion reporting less than 12th grade education 
level. Depo-Provera (23%-29%) and condoms (22%-27%) were the common birth control 
methods that were used and there were no significant differences between the three groups. The 
median number of life-time male sexual partners significantly differed between the groups 
(p=0.007) with the STI co-infection group having a larger number of partners compared to the no 
infection and single infection groups. Women who had STI co-infections were marginally (p=0.10) 
more likely to have abnormal cervical cytology (14%) compared to women who had no infection 
(4%) or had single infection (10%).  
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Table 1a. Demographic and sexual health characteristics of women in the EVRI Trial comparing 
women with and without STIs (Any HPV, Chlamydia, Gonorrhea, Syphilis, or HSV-2) 
 
  No Infection 
(n=48) 
Single Infection  
(n=131) 
Co-infection 
(n=209) 
 
P-valuea 
N (%) N (%) N (%) 
Median age in years (range) 20(16-24) 21(16-24) 20(16-24) 0.24 
             16-18  12 (25.0) 22(16.7) 48(22.9)  
             19-21 24(50.0) 64(48.8) 103(49.2)  
              22-24 12(25.0) 45(34.3) 58(27.7)  
Marital status    0.31 
       Single/Widowed 44(91.6) 125(95.4) 202(96.6)  
       Married/Living Together 4(8.3) 6(4.5) 7(3.3)  
Education    0.02 
            ≤ Grade 7 6(12.5) 3(2.2) 10(4.7)  
            Grade 8-12 21(43.7) 65(49.6) 126(60.2)  
             Passed Grade 12 11(22.9) 33(25.1) 34(16.2)  
             Some college/tech 10(20.8) 30(22.9) 39(18.6)  
Median age of first vaginal 
sex (range) 
16(13-19) 17(13-21) 17(1-21) 0.33 
Currently using birth controlb 21(43.7) 62(47.3) 101(48.3) 0.81 
Current birth control use     
         Oral contraceptives 1(2.0) 6(4.5) 7(3.3) 0.69 
          IUD/loop/coil 0(0.0) 1(0.7) 1(0.4) 0.81 
          Depo Provera 11(22.9) 38(29.0) 50(23.9) 0.52 
          Condoms 13(27.0) 29(22.1) 50(23.9) 0.78 
Ever been pregnant 21(43.7) 67(51.1) 104(49.7) 0.67 
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Table 1a. (Continued) 
 No Infection 
(n=48) 
Single Infection  
(n=131) 
Co-infection 
(n=209) 
 
P-valuea N (%) N (%) N (%) 
Lifetime no. of male sexual 
partnersc; median (range)  
2 (1-17) 2(1-22) 3(1-24) 0.0074 
           1 10(33.3) 18(18.1) 27(16.3)  
          2 11(36.6) 32(32.3) 44(26.6)  
           3+ 9(30.0) 49(49.4) 94(56.9)  
Number of sexual partners in 
the past 6 monthsd; median 
(range) 
1(0-3) 1(0-5) 1(0-5) 0.48 
          0 2(8.3) 6(8.1) 8(6.3)  
          1 19(79.1) 56(75.6) 91(72.2)  
          2 2(8.3) 8(10.8) 21(16.6)  
          3+ 1(4.1) 4(5.4) 6(4.7)  
Ever received money/drugs/ 
presents for sex 
3(6.2) 5(3.8) 5(2.3) 0.38 
Cervical Cytologye    0.10 
          Normal 46(95.8) 118(90.0) 179(85.6)  
          Abnormal 2(4.1) 13(9.9) 30(14.3)  
Bold text denotes statistically significant findings  
a P-value calculated as based on Pearson-Chi Square test for categorical variables and Wilcoxon Mann-Whitney test 
for continuous variables 
b sample size reduced due to missing values (n=134) ; 
 c,d sample size reduced due to missing values (n=94) and (n=164) respectively ;  
e abnormal cervical cytology= High grade Squamous intraepithelial lesion(HSIL) or Low grade Squamous 
intraepithelial lesion(LSIL); normal cervical cytology= negative pap test or atypical cells of undetermined significance 
(ASCUS) 
 
Demographic Characteristics (HR-HPV) 
The median age of participants among the single infection and co-infection groups was 20 years 
(range, 16-24) whereas it was 20.5 years for the no infection group (range, 16-24) (Table 1b). 
The majority of the participants in all three groups were either single or widowed and the majority 
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of them had not passed grade 12. Presence of abnormal cervical cytology did statistically 
significantly (p=0.02) differ between the three groups, with women who had STI co-infections 
more likely to have abnormal cervical cytology (15%), compared with the single infection (11%) 
and no infection (3%) groups. However, there was no other statistically significant difference in 
the demographic and sexual behavior between the three groups of women.  
Table 1b. Demographic and sexual health characteristics of women in the EVRI Trial comparing 
women with and without STIs (HR- HPV, Chlamydia, Gonorrhea, Syphilis, or HSV-2) 
  No Infection 
(n=68) 
Single Infection  
(n=138) 
Co-infection 
(n=182) 
 
P-valuea 
N (%) N (%) N (%) 
Median age in years 
(range) 
20.5(16-24) 20(16-24) 20(16-24) 0.58 
             16-18  15(22.0) 26(18.8) 41(22.5)  
             19-21 30(44.1) 69(50.0) 92(50.5)  
              22-24 23(33.8) 43(31.1) 49(26.9)  
Marital status    0.37 
     Single/Widowed 63(92.6) 132(95.6) 176(96.7)  
     Married/Living Together 5(7.3) 6(4.3) 6(3.3)  
Education    0.11 
            ≤ Grade 7 7(10.2) 5(3.6) 7(3.8)  
            Grade 8-12 28(41.1) 75(54.3) 109(59.8)  
             Passed Grade 12 16(23.5) 30(21.7) 32(17.5)  
             Some college/tech 17(25.0) 28(20.2) 34(18.6)  
Median age of first vaginal 
sex (range) 
16(13-19) 17(13-21) 17(1-21) 0.94 
Currently using birth 
controlb 
30(44.1) 67(48.5) 87(47.8) 0.95 
Current birth control use     
         Oral contraceptives 1(1.4) 7(5.0) 6(3.3) 0.40 
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Table 1b. (Continued) 
 No Infection 
(n=68) 
Single Infection  
(n=138) 
Co-infection 
(n=182) 
 
P-valuea N (%) N (%) N (%) 
          IUD/loop/coil 0(0.0) 2(1.4) 0(0.0) 0.16 
          Depo Provera 19(27.9) 37(26.8) 43(23.6) 0.71 
          Condoms 15(22.0) 32(23.1) 45(24.7) 0.89 
Ever been pregnant 31(45.5) 71(51.4) 90(49.4) 0.73 
Lifetime no. of male sexual 
partnersc; median (range)  
2 (1-22) 2.5(1-21) 3(1-24) 0.09 
           1 11(24.4) 21(19.8) 23(16.0)  
           2 16(35.5) 32(30.1) 39(27.2)  
           3+ 18(40.0) 53(50.0) 81(56.6)  
Number of sexual partners 
in the past 6 monthsd; 
median (range) 
1(0-3) 1(0-5) 1(0-5) 0.32 
          0 2(5.8) 8(9.6) 6(5.6)  
          1 28(82.3) 61(73.4) 77(71.9)  
          2 2(5.8) 11(13.2) 18(16.8)  
          3+ 2(5.8) 3(3.6) 6(5.6)  
Ever received money/drugs/ 
presents for sex 
4(5.8) 4(2.9) 5(2.7) 0.44 
Cervical Cytologye    0.02 
          Normal 66(97.0) 123(89.1) 154(84.6)  
          Abnormal 2(2.9) 15(10.8) 28(15.3)  
Bold text denotes statistically significant findings  
a P-value calculated as based on Pearson-Chi Square test for categorical variables and Wilcoxon Mann-Whitney test 
for continuous variables 
b sample size reduced due to missing values (n=134) ; 
 c,d sample size reduced due to missing values (n=94) and (n=164) respectively ;   
e abnormal cervical cytology= High grade Squamous intraepithelial lesion(HSIL) or Low grade Squamous 
intraepithelial lesion(LSIL); normal cervical cytology= negative pap test or atypical cells of undetermined significance 
(ASCUS) 
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Prevalence of STIs (Any HPV) 
Prevalence of STI co-infections was high in the women enrolled in the EVRI Trial (Table 2). 
Among women with only a single infection, the prevalence of HPV (67%, n=88) was the highest 
(Figure 3a), followed by the prevalence of HSV-2 (19%, n=25), chlamydia (CT) (11%, n=14), and 
syphilis (SY) (3%, n=4). Gonorrhea (GN) was not seen as an isolated single infection in any 
enrolled women. The most common STI co-infection pattern was HPV-HSV (32%, n=67), followed 
by HPV-CT (17%, n=35); for three concurrent STI co-infections it was HPV-HSV-CT (16%, n=34) 
(Figure 3b). The most common four concurrent STI co-infections was HPV-CT-GN-HSV (7%, 
n=15) and about 1% (n=2) of enrolled women had all five STIs (HPV-CT-GN-SY-HSV) assessed. 
Table 2: STI co-infection patterns of women in the EVRI Trial (Any HPV/ HR- HPV, Chlamydia, 
Gonorrhea, Syphilis, or HSV-2) 
 
Nature of infections Any HPV 
% (n) 
HR-HPV 
%(n) 
No infection at all 12.3 (48)  17.5 (68)  
   
Single Infection   
      HPV only 22.6 (88)  17.5 (68) 
      Chlamydia only 3.6 (14)  5.4 (21)  
      Gonorrhea only  0.0 (0)  0.0 (0)  
      Syphilis only 1.0 (4)  1.0 (4)  
      HSV only 6.4 (25)  11.5 (45)  
   
2 Co-infections   
      HPV + Chlamydia  9.0 (35)  7.2 (28)  
      HPV + Gonorrhea 1.2 (5)  1.2 (5)  
      HPV + Syphilis 0.5 (2) 0.5 (2)  
      HPV + HSV 17.2 (67)  12.1 (47)  
      Chlamydia + Gonorrhea 0.5 (2)  1.0 (4)  
      Chlamydia + Syphilis 0.0 (0)  0.0 (0)  
      Chlamydia + HSV 3.3 (13)  4.1 (16)  
      Gonorrhea + Syphilis 0.0 (0)  0.0 (0)  
      Gonorrhea + HSV 0.8 (3)  1.0 (4)  
      Syphilis + HSV 0.0 (0)  1.0 (4)  
   
3 Co-infections   
      HPV + Chlamydia+ Gonorrhea 2.3 (9)  1.8 (7)  
      HPV + Chlamydia + Syphilis 0.5 (2)  0.5 (2)  
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Table 2. (Continued) 
Nature of infections Any HPV 
% (n) 
HR-HPV 
%(n) 
      HPV + Chlamydia + HSV 8.7 (34)  7.9 (31)  
      HPV + Gonorrhea + Syphilis 0.0 (0)  0.0 (0)  
      HPV + Gonorrhea + HSV 1.2 (5)  1.0 (4)  
      HPV + HSV + Syphilis 2.8 (11)  1.8 (7)  
      Chlamydia + Gonorrhea + Syphilis 0.0 (0)  0.0 (0) 
      Chlamydia + Gonorrhea + HSV 0.5 (2)  0.8 (3)  
      Gonorrhea + Syphilis + HSV 0.0 (0)  0.0 (0)  
      Chlamydia + Syphilis + HSV  0.0 (0)  0.0 (0)  
   
4 Co-infections   
      HPV + Chlamydia+ Gonorrhea + Syphilis 0.0 (0)  0.0 (0)  
      HPV + Chlamydia+ Gonorrhea + HSV 3.8 (15)  3.6 (14)  
      HPV + Chlamydia+ HSV + Syphilis 0.5 (2)  0.5 (2)  
      HPV + Gonorrhea + HSV + Syphilis  0.0 (0)  0.0 (0)  
      Chlamydia + Gonorrhea + Syphilis + HSV 0.0 (0)  0.2 (1) 
   
5 Co-infections 0.5 (2)  0.2 (1)  
 
  
Figure 3a: STI infection patterns of women in the EVRI Trial with at least 1 STI (HPV=Any HPV, 
CT=Chlamydia, GN=Gonorrhea, SY=Syphilis, or HSV=Herpes Simplex -2) 
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Figure 3b: STI co-infection patterns of women in the EVRI Trial with at least 1 STI (HPV=Any 
HPV, CT=Chlamydia, GN=Gonorrhea, SY=Syphilis, or HSV=Herpes Simplex -2) 
 
Prevalence of STIs (HR-HPV) 
Prevalence of co-infection was high among the women enrolled in the EVRI Trial when HPV 
infection was also restricted to HR-HPVs (Table 2). Among women with only a single STI, high- 
risk HPV had the highest prevalence at 49% (n=68) (Figure 3c), followed by HSV-2 (33%, n=45), 
CT infection (15%, n=21), and SY (3%, n=4). GN was not seen as an isolated single infection in 
any enrolled women. The most common co-infection pattern seen was High-risk HPV-HSV (26%, 
n=47), followed by High-risk HPV-CT (15%, n=28) looking at two STI co-infection followed by a 
co-infection with High-risk HPV-HSV-CT (17%, n=31) for a three STI co-infection pattern. The 
most common four concurrent STI co-infection pattern was seen for High-risk HPV-CT-GN-HSV 
(8%, n=14) and again about 1% (n=1) of enrolled women had all five STIs (High-risk HPV-CT-
GN-SY-HSV) assessed. 
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Figure 3c: STI co-infection patterns of women in the EVRI Trial with at least 1 STI (HPV=HR-HPV, 
CT=Chlamydia, GN=Gonorrhea, SY=Syphilis, or HSV=Herpes Simplex -2) 
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Factors Associated with STIs (Any HPV) 
An unadjusted polytomous logistic regression analysis was used to identify the factors associated 
with single STI infection and STI co-infection compared to women with no STIs (Table 3a). The 
odds of a single infection and co-infection compared to no infection were non-significantly lower 
for ages 19-21 (OR 0.71, 95%CI: 0.32-1.56 for single STI infection and OR 0.88, 95% CI: 0.41-
1.90 for STI co-infection) and ages 16-18 (OR 0.48, 95%CI: 0.18-1.26 for single STI infection and 
OR 0.82, 95% CI: 0.34-2.00 for STI co-infection) when compared to ages 22-24. The odds of 
having a single STI infection (OR 0.52, 95% CI: 0.14-1.95) or STI co-infection (OR 0.38, 95%CI: 
0.10-1.35) was non-significantly lower in women who were married or living with partners 
compared to women who were single or widowed. Higher education was associated with lower 
odds of having an STI compared to no infection. The odds of single STI infection compared to no 
infection was significantly lower for women who had education level of grade 7 compared to 
women who had some college or technical education (unadjusted OR (uOR) 0.16, 95% CI: 0.03-
0.79). The odds of a single STI infection compared to no infection were significantly higher (uOR 
3.02, 95% CI: 1.05-8.64) for women with three or more lifetime partners compared to one life time 
partner. Similarly, the odds of a STI co-infection compared to no infection were significantly higher 
for women with three or more lifetime partners compared to one life time partner (uOR 3.86, 95% 
CI: 1.42-10.48). When we performed the backward selection model, the odds of STI co-infection 
was significantly higher in women who had three or more than three lifetime number of male 
sexual partners compared to women who had one lifetime male sexual partners (adjusted OR 
(aOR)  3.68, 95% CI: 1.14-11.90).  
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Table 3a. Factors associated with single STI (Any HPV, Chlamydia, Gonorrhea, Syphilis, or  
 HSV-2) infection and STI co-infections compared to women with no infection among women in 
 the EVRI Trial 
 
  Single Infection  (n=131) Co-infections (n=209) 
uORa 
(95% CI)  
aORb 
(95% CI) 
uORa  
(95% CI) 
aORb  
(95% CI) 
Age in years    
  22-24 1.00(Ref)  1.00(Ref)  
19-21 0.71(0.32-1.56) 1.43(0.46-4.40) 0.88(0.41-1.90) 1.47(0.49-4.37) 
  16-18 0.48(0.18-1.26) 0.51(0.13-1.98) 0.82(0.34-2.00) 1.05(0.30-3.58) 
Marital status   
  Single/Widowed 1.00(Ref)  1.00(Ref)  
  Married/Living Together 0.52(0.14-1.95)  0.38(0.10-1.35)  
Education   
  Some college/tech 1.00(Ref)  1.00(Ref)  
   ≤ Grade 7 0.16(0.03-0.79)  0.42(0.12-1.45)  
  Grade 8-12 1.03(0.43-2.45)  1.53(0.66-3.54)  
   Passed Grade 12 1.00(0.37-2.68)  0.79(0.30-2.09)  
Currently using Birth  
Controlc 
  
   Yes 1.00(Ref)  1.00(Ref)  
    No 1.25(0.47-3.32)  1.09(0.43-2.79)  
Ever been Pregnant   
    Never 1.00(Ref)  1.00(Ref)  
    Ever 0.74(0.38-1.44)  0.78(0.41-1.47)  
Lifetime no. of male 
sexual partnersd 
  
    1 1.00(Ref) 1.00(Ref) 1.00(Ref) 1.00(Ref) 
    2 1.61(0.57-4.54) 2.18(0.59-7.95) 1.48(0.55-3.95) 1.98(0.60-6.50) 
    3+ 3.02(1.05-8.64) 3.28(0.92-11.67) 3.86(1.42-10.48) 3.68(1.14-11.90) 
Number of sexual 
partners in the past 6 
monthse 
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Table 3a. (Continued) 
 Single Infection  (n=131) 
 
Co-infections (n=209) 
uORa 
(95% CI)  
aORb 
(95% CI) 
uORa  
(95% CI) 
aORb  
(95% CI) 
    0 1.00(Ref)  1.00(Ref)  
    1 0.98(0.18-5.28)  1.19(0.23-6.09)  
    2+ 1.33(0.14-12.36)  2.25(0.31-15.90)  
Cervical Cytologyf   
     Normal 1.00(Ref)  1.00(Ref)  
    Abnormal 2.53(0.55-11.64) 2.77(0.32-23.93) 3.85(0.88-16.69) 3.74(0.46-30.10) 
Abbreviations: HPV: human papillomavirus; 95% CI: 95% Confidence Interval; ref: reference group  
Bold text denotes statistically significant findings  
a uOR: unadjusted Odds ratio;  baOR: adjusted odds Ratio; 
c sample size reduced due to missing values (n=134) ; 
 d,e sample size reduced due to missing values (n=94) and (n=164) respectively ;  
f abnormal cervical cytology= High grade Squamous intraepithelial lesion(HSIL) or Low grade Squamous intraepithelial lesion(LSIL); 
normal cervical cytology= negative pap test or atypical cells of undetermined significance (ASCUS) 
g uOR was estimated by multinomial logistics regression model/link=glogit function; 
h aOR was estimated by multinomial logistics regression model using /link=glogit function and using a backward selection procedure 
with a stay p-value of 0.20. Variables age, lifetime number of male sexual partners and cervical cytology were forced in the adjusted 
model.  
 
Factors Associated with STIs (HR-HPV) 
When the analysis was restricted to women who were infected with high risk HPV (HR-HPV) 
types, no independent risk factor was statistically significantly associated with the risk of single 
STI infection compared to no infection in the unadjusted model. However, the odds of STI co-
infection was significantly higher in women who had abnormal cervical cytology, categorized as 
presence of High–grade and Low-grade squamous intraepithelial lesion (HSIL/LSIL), compared 
to women who had no infection (uOR 6.00, 95% CI: 1.38-25.91) (Table 3b). When we performed 
the backward selection model, the odds of STI co-infection compared to no infection was 
significantly higher in women who had three or more than three lifetime number of male sexual 
partners compared to women who had one lifetime male sexual partners (aOR 3.10, 95% CI: 
1.02-9.34). 
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Table 3b. Factors associated with single STI (HR-HPV, Chlamydia, Gonorrhea, Syphilis, or  
 HSV-2) infection and STI co-infections compared to women with no infection among women in 
 the EVRI Trial 
 
  Single Infection  (n=138) Co-infections (n=182) 
uORa   
(95% CI) 
aORb  
 (95% CI) 
uORa  
(95% CI) 
aORb  
 (95% CI) 
Age in years    
  22-24 1.00(Ref)  1.00(Ref)  
  19-21 1.23(0.63-2.38) 1.36(0.53-3.51) 1.43(0.75-2.74) 1.56(0.61-3.97) 
  16-18 0.92(0.41-2.08) 0.69(0.20-2.30) 1.28(0.59-2.77) 1.50(0.49-4.63) 
Marital status   
     Single/Widowed 1.00(Ref)  1.00(Ref)  
  Married/Living together 0.57(0.16-1.94)  0.43(0.12-1.45)  
Education   
 Some college/tech 1.00(Ref)  1.00(Ref)  
  ≤ Grade 7 0.43(0.11-1.58)  0.50(0.15-1.65)  
  Grade 8-12 1.62(0.77-3.41)  1.94(0.95-3.97)  
  Passed Grade 12 1.13(0.48-2.67)  1.00(0.43-2.30)  
Currently using Birth 
Controlc 
  
             Yes 1.00(Ref)  1.00(Ref)  
             No 0.89(0.40-1.97)  0.82(0.38-1.77)  
Ever been Pregnant   
             Never 1.00(Ref)  1.00(Ref)  
             Ever 0.79(0.44-1.41)  0.85(0.49-1.49)  
Lifetime no. of male 
sexual partnersd 
  
           1 1.00(Ref) 1.00(Ref) 1.00(Ref) 1.00(Ref) 
           2 1.04(0.40-2.69) 1.46(0.45-4.66) 1.16(0.46-2.93) 2.01(0.64-6.34) 
           3+ 1.54(0.62-3.81) 1.99(0.65-6.06) 2.15(0.89-5.19) 3.10(1.02-9.34) 
Number of sexual 
partners in the past 6 
monthse 
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Table 3b. (Continued) 
 Single Infection  (n=138) 
 
Co-infections (n=182) 
 
 uORa 
(95% CI)  
aORb 
(95% CI) 
uORa 
(95% CI)  
aORb 
(95% CI) 
          0 1.00(Ref)  1.00(Ref)  
          1 0.54(0.10-2.73)  0.91(0.17-4.81)  
          2 0.87(0.13-5.89)  2.00(0.29-13.62)  
Cervical Cytologyf     
          Normal 1.00(Ref)  1.00(Ref)  
          Abnormal 4.02(0.89-
18.13) 
4.51 (0.54-37.08) 6.00(1.38-25.91) 5.74(0.72-45.75) 
Abbreviations: HPV: human papillomavirus; 95% CI: 95% Confidence Interval; ref: reference group  
Bold text denotes statistically significant findings  
a uOR: unadjusted Odds ratio;  baOR: adjusted odds Ratio; 
c sample size reduced due to missing values (n=134) ; 
 d,e sample size reduced due to missing values (n=94) and (n=164) respectively ;  
f abnormal cervical cytology= High grade Squamous intraepithelial lesion(HSIL) or Low grade Squamous intraepithelial lesion(LSIL); 
normal cervical cytology= negative pap test or atypical cells of undetermined significance (ASCUS) 
g uOR was estimated by multinomial logistics regression model/link=glogit function; 
h aOR was estimated by multinomial logistics regression model using /link=glogit function and using a backward selection procedure 
with a stay p-value of 0.20. Variables age, lifetime number of male sexual partners and cervical cytology were forced in the adjusted 
model.  
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Discussion 
We have described the prevalence of HPV and other common STIs along with factors associated 
with single infection and coinfection among young South African women who participated in the 
EVRI Trial. STIs were common and the women with STIs were likely to have multiple co-
infections. This high STI prevalence may have an alarming impact on the women’s reproductive 
health and potential future impact on pregnancy birth outcomes. It highlights the need for an 
effective and coordinated intervention for HPV and other common STIs. 
 Overall prevalence of a single STI and STI co-infections are consistent with similar studies 
performed in the sub-Saharan African region. Our study showed an overall chlamydia prevalence 
of 33%. A study conducted in Mozambique showed that the overall prevalence of chlamydia 
infection was 8% [8] while another study among women in South Africa showed chlamydia 
prevalence of 19.5%.[16] In Uganda, prevalence of chlamydia in female adolescents was 
4.5%.[24] Women with chlamydia infection were shown to be at high risk of acquiring gonorrhea 
and vice-versa.[16] Our study showed an overall syphilis prevalence of 6%. A study conducted 
among women in rural sub-Saharan Africa showed that prevalence of syphilis was 12% [8] while 
another study reported prevalence of 7.5% [16] in South Africa. In a cohort of women from rural 
Tanzania, syphilis prevalence was reported to be 9.1%.[25] The high prevalence of bacterial STIs 
is not consistently seen across countries but rather seems to be country specific.[10]  One of the 
reasons for this might be the difference in the sensitivity of the assays used for detection.[16] 
Overall prevalence of HSV-2 antibodies were high in our study at 46%. Prevalence of HSV-2 
among women in rural sub- Saharan Africa was 83% in one study. [8] Similar studies in South 
Africa reported an HSV-2 prevalence estimate between 40-70%.[26] The high prevalence of HSV-
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2 is particularly important as it has been shown that HSV-2 increases the susceptibility of HIV 
transmission and HSV-2 seropositivity has been attributed as a marker of sexual health behavior 
among adolescents.[17, 18] 
The overall prevalence of HPV in this study was high at 71% as previously reported from the EVRI 
trial.[10] In one study cervical HPV prevalence was estimated at  22% among women in Africa [7] 
and among women in rural sub Saharan Africa, another study reported an HPV prevalence of 
40%.[8] A comprehensive meta-analysis of HPV prevalence from 71 studies from 23 African 
countries showed that there is regional variation with Southern Africa having the highest 
prevalence (57%) followed by Eastern Africa (42%), Western Africa (29%) and Northern Africa 
(13%).[27] HPV prevalence in our study might have been higher compared to these studies 
because of the age of women enrolled in the EVRI trial and the study site for trial being chosen 
based on the clinical data that showed high prevalence of HIV in the area. It has been shown 
consistently across studies that HPV prevalence decreases with increasing age from a peak 
prevalence in younger women (<=25 years of age).[28] HPV prevalence in our study is 
comparable with data seen among female sex workers and HIV-positive women in Africa, where 
the prevalence ranged from 39-71%.[29] High prevalence of HPV in these studies of young 
women suggests that vaccination against HPV needs to be started early in HPV high-risk 
communities. Co-infection with other STIs like chlamydia and HSV-2 are significant risk factors 
for increased HPV infection.[30] High prevalence of chlamydial infection in these study 
populations has a positive association with HR-HPV persistence and regular screening and 
management of STIs are a potential prevention strategies to reduce HR-HPV persistence and 
related adverse health outcomes among women.[6] 
We observed a strong association between the lifetime number of male sexual partners and risk 
of an STI or STI co-infections. The odds of a single STI and STI co-infection compared to no 
infection were significantly higher for women with three or more lifetime partners compared to one 
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life time partner. These findings are consistent with a study carried out in three different African 
countries, South Africa, Zambia and Tanzania, that showed that having two or more male sexual 
partners, being unmarried and having higher education were independent risk factors for getting 
a STI.[16] A longitudinal study among young adolescent women showed that having a new sexual 
partner results in a 10-fold increased risk for getting HPV. [31]  High-risk sexual behaviors like 
multiple sexual partners and non-use of condoms are usually associated with increased risk of 
STIs. Behavioral interventions have been promoted as an essential tool to combat the 
transmission of STIs worldwide. We found that higher education increased the risk of an STI 
infection. The formation of “sexual partnerships” play a key role in the transmission dynamics of 
STIs and places that offer higher education (college, universities) are the most common places 
for forming these partnerships.[4] Similarly, when restricted to analysis among high-risk HPV 
positive women, the odds of STI co-infection compared to no infection was significantly higher for 
women with abnormal cytology compared to normal cytology. Although the temporality of this 
association cannot be explained, it has been shown that early sexual activity and the presence of 
STIs accelerates the process of cervical maturation, which in the presence of a persistent HPV 
infection, induces genetic alteration in the epithelium that can lead to high-grade squamous 
intraepithelial lesions.[31] 
There are several strengths and limitations to the current study which need to be considered in 
interpreting the data and drawing conclusions. A major strength of our study is the large sample 
size that allowed us to quantify STI prevalence and describe co-infections with STIs. Syndromic 
management is the treatment of choice for many STIs and our prevalence data show it remains 
ineffective among young adolescents in developing countries, as many of the infections we 
detected were asymptomatic. 
Since the EVRI baseline data were obtained indirectly using tablet- based questionnaires, data 
on sexual and behavioral characteristics might have been affected by social-desirability bias. This 
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could potentially introduce misclassification into our study due to underestimation of the reported 
number of lifetime male sexual partners which might have affected the capability to assess 
associations. Also, the tablet-based questionnaire was a source of initial confusion in the trial as 
116 participants reported not having had vaginal intercourse during the eligibility screening. The 
study site for the EVRI trial was chosen based on the clinical data that showed high prevalence 
of HIV in the area. Therefore, our study findings might not be generalizable to all South African 
women. Our study also is likely to be underpowered for some of the tested associations. There 
might have been suggestive associations that might have been significant with a larger sample. 
STIs like HPV were based on DNA detection whereas other STIs like HSV-2 were based on 
serology that might not be a reflection of the current infection status. Lastly, the prevalence of 
other important STIs, like trichomonas was not measured in the EVRI trial.  
The data from the EVRI trial clearly demonstrate that behavioral risk factors play an important 
role in STI prevalence. These results strengthen the recommendation that STI screening and 
treatment needs to be a component of multiple intervention strategies among high-risk women, 
such as those residing in communities with high STI prevalence. For HPV infections, recent 
developments in vaccines offers a lot of hope, but the challenge remains on the affordability and 
availability of these in rural areas where HPV is prevalent. A transdisciplinary prevention approach 
involving vaccines, effective treatments, behavioral interventions, counseling, proper education, 
elaborate community participation and effective health care policy is needed to have a 
measurable impact on highly prevalent STIs in these population of young women.  
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Appendix A: Eligibility Criteria 
 
1. Are you between 16-24 years of age?     Yes No 
2. Have you ever had an abnormal Pap smear ?    Yes No 
3. Have you ever had vaginal intercourse?     Yes No 
4. Are you currently pregnant?       Yes No 
5. Are you currently breastfeeding?      Yes No 
6. Have you ever been diagnosed with AIDS or HIV?    Yes No 
7. Do you have an autoimmune disease for which you are taking steroids?  Yes No 
8. Have you had a splenectomy?      Yes No 
9. Are you currently taking part in an HIV prevention trial?   Yes No 
10. Are you now or have you during past 6 months used IV drugs or TIK? Yes No 
11. Do you have any history of serious allergic reaction requiring  
Medical attention?         Yes No 
12. Do you have a known allergy to Aluminum, Yeast or Benzonase?  Yes No 
13. Have you ever received a marketed HPV vaccine?    Yes No 
14. Are you willing to comply with 4 scheduled visits within the next  
7 months?         Yes No 
15. Do you agree to use effective contraception during sexual  
Intercourse (excluding the rhythm method or withdrawal) during  
the vaccination period?       Yes No 
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long-term follow-up of subjects; or (b) where no subjects have been enrolled and no additional 
risks have been identified; or (c) where the remaining research activities are limited to data 
analysis. 
 
Per CFR 45 Part 46, Subpart D, this research involving children was approved under the greater 
than minimal risk category 45 CFR 46.405: Research is greater than minimal risk with the 
prospect of direct benefit to the participant. 
 
As the principal investigator of this study, it is your responsibility to conduct this study in 
accordance with USF HRPP policies and procedures and as approved by the USF IRB. Any 
changes to the approved research must be submitted to the IRB for review and approval by an 
amendment. Additionally, all unanticipated problems must be reported to the USF IRB within 
five (5) calendar days. 
 
We appreciate your dedication to the ethical conduct of human subject research at the University 
of South Florida and your continued commitment to human research protections. If you have any 
questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
 
 
 
 
E. Verena Jorgensen, M.D., Chairperson 
USF Institutional Review Board 
 
